stockrowRxSight, Inc.
RXST Healthcare Medical Devices
RxSight, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $134.5 million, down 3.89% from fiscal 2024.
- Revenue
- −19.0%
- EPS
- −62.1%
- Free cash flow
- +2,591.1%
Quarter to September 2026, against a year earlier
Follow RXST
Alert me
RxSight, Inc. (RXST) EV/Sales
As of 5 November 2026, RxSight, Inc. (RXST) trades at a EV/Sales of −0.4×. Over the past ten years it has ranged from −0.4× (November 2026) to 22.4× (May 2024) — the current reading is the lowest in ten years. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.6× | (79.80%) |
| FY2024 | 8.0× | (38.35%) |
| FY2023 | 13.0× | 120.75% |
| FY2022 | 5.9× | 293.75% |
| FY2021 | 1.5× | (47.64%) |
| FY2020 | 2.8× | 0.00% |
| FY2019 | 2.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | −0.3× | — |
| Jun 2026 | 0.1× | (80.82%) |
| Mar 2026 | 0.4× | (72.72%) |
| Dec 2025 | 1.6× | 43.07% |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LAB Standard BioTools Inc. compare | −2.5× |
| RXST RxSight, Inc. | −0.4× |
| INGN Inogen, Inc compare | 0.2× |
| STIM Neuronetics, Inc. compare | 1.5× |
| INFU InfuSystems Holdings, Inc. compare | 2.0× |
| ELMD Electromed, Inc. compare | 2.7× |
| TLSI TriSalus Life Sciences, Inc. compare | 4.3× |
| PROF Profound Medical compare | 9.6× |
| QSI Quantum-Si Incorporated compare | 121× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)